...
首页> 外文期刊>Journal of Korean medical science. >Thoracic Air-leak Syndromes In Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease: A Possible Sign for Poor Response to Treatment and Poor Prognosis
【24h】

Thoracic Air-leak Syndromes In Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease: A Possible Sign for Poor Response to Treatment and Poor Prognosis

机译:移植物抗宿主病的造血干细胞移植患者的胸漏综合征:对治疗反应不良和预后不良的可能征象

获取原文
           

摘要

Bronchiolitis obliterans (BO) or bronchiolitis obliterans organizing pneumonia (BOOP) is one of manifestations of graft-versus-host disease (GVHD), a complication of hematopoietic stem cell transplantation (HSCT). Recently there are reports about thoracic air-leakage syndrome (TALS), but real incidence, clinical course, and implications of TALS remain unclear. Retrospective review of 18 TALS patients among 2,177 patients who received allogeneic HSCT between January 2000 to July 2007 was done. Clinical manifestations, treatments, and outcomes of TALS were reviewed. The incidence of TALS was 0.83% (18/2,177). The onset of TALS was mean 425.9±417.8 days (60-1,825 days) after HSCT, and the duration was mean 16.3±21 days (2-90 days). The most common types of TALS were spontaneous pneumothroax (n=14), followed by subcutaneous emphysema (n=6), pneumomediastinum (n=5), interstitial emphysema (n=2), and pneumopericardium (n=1). TALS persisted in six patients, who died during the same hospitalization. The 12 patients recovered from TALS, but only 2 survived, while others died due to aggravation of GVHD. TALS may complicate BO/BOOP and be an initial manifestation of BO/BOOP. TALS is hard to be resolved, and even after the recovery, patients die because of aggravation of GVHD. We suggest specifically in HSCT patients, when once developed, TALS seems hard to be cured, and as a result, be related to high fatality.
机译:闭塞性细支气管炎(BO)或组织性肺炎的闭塞性细支气管炎(BOOP)是移植物抗宿主病(GVHD)的一种表现,这是造血干细胞移植(HSCT)的并发症。最近有关于胸漏气综合征(TALS)的报道,但是TALS的实际发病率,临床病程和意义尚不清楚。回顾性分析了2000年1月至2007年7月间接受异基因HSCT的2177例患者中的18例TALS。回顾了TALS的临床表现,治疗方法和结局。 TALS的发生率为0.83%(18 / 2,177)。 TALS的发作在HSCT后平均为425.9±417.8天(60-1,825天),持续时间平均为16.3±21天(2-90天)。 TALS最常见的类型是自发性气胸(n = 14),其次是皮下气肿(n = 6),纵隔气肿(n = 5),间质性气肿(n = 2)和气腹心包(n = 1)。 TALS持续存在六名患者,他们在同一住院期间死亡。 12例患者从TALS中康复,但只有2例幸存,而其他人则因GVHD恶化而死亡。 TALS可能会使BO / BOOP变得复杂,并且是BO / BOOP的最初表现。 TALS难以解决,即使康复,患者也会因GVHD恶化而死亡。我们建议特别针对HSCT患者,一旦发展起来,TALS似乎很难治愈,因此与高死亡率相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号